2022
DOI: 10.1097/ju.0000000000002594.05
|View full text |Cite
|
Sign up to set email alerts
|

Pd36-05 loss-of-Function in Phf7 Cause Male Infertility by Impairing Histone-to-Protamine Exchange During Spermiogenesis

Abstract: timepoints. A subcohort of animals (n[3) also underwent a 140 day period of THC discontinuation with testicular, serum and semen evaluations at 70 and 140 days. Random intercept mixed effects models with a linear spline at start of THC abstinence were used to determine the average change in testes, serum, and semen measurements with increasing THC dose and after discontinuation.RESULTS: For every 1 mg/7 kg/day increase in THC dosing, there was a significant decrease in total testicular volume bilaterally by 13… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…Notable genes amongst these 22 include eight associated with male fertility (MOV10L1 (Fu et al, 2016), PHF7 (Cheng et al, 2023), ABHD10 (Smith and Eppig, 2009), CFAP119 (Iso-Touru et al, 2019), MARCHF6 (Smith and Eppig, 2009), MAGEB4 (Okutman et al, 2017), DEFB116 (Caballero-Campo et al, 2014;Zhang et al, 2018), and ARL13A (Schürmann et al, 2002)); immunity (DEFB116 (Schröder and Harder, 1999;Schneider et al, 2005;Dhople et al, 2006), ARL13A (Song and Perkins, 2018), and IGBP1C (Smith and Eppig, 2009)); cancer (SSX5 (Smith and McNeel, 2010), TNFAIP1 (Tian et al, 2015), PRSS3 (Hockla et al, 2012), SLC38A7 (Haratake et al, 2021), and HAS3 (Wang et al, 2022)); and developmental defects (NCDN (Fatima et al, 2021)).…”
Section: Discussionmentioning
confidence: 99%
“…Notable genes amongst these 22 include eight associated with male fertility (MOV10L1 (Fu et al, 2016), PHF7 (Cheng et al, 2023), ABHD10 (Smith and Eppig, 2009), CFAP119 (Iso-Touru et al, 2019), MARCHF6 (Smith and Eppig, 2009), MAGEB4 (Okutman et al, 2017), DEFB116 (Caballero-Campo et al, 2014;Zhang et al, 2018), and ARL13A (Schürmann et al, 2002)); immunity (DEFB116 (Schröder and Harder, 1999;Schneider et al, 2005;Dhople et al, 2006), ARL13A (Song and Perkins, 2018), and IGBP1C (Smith and Eppig, 2009)); cancer (SSX5 (Smith and McNeel, 2010), TNFAIP1 (Tian et al, 2015), PRSS3 (Hockla et al, 2012), SLC38A7 (Haratake et al, 2021), and HAS3 (Wang et al, 2022)); and developmental defects (NCDN (Fatima et al, 2021)).…”
Section: Discussionmentioning
confidence: 99%